Product Pipeline
  • 2008

    12 February 2008: Press release no. 1, 2008: Phase III program for AVE0010/ZP10 licensed ...

    Read More >

  • Product Pipeline

    Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and ...

    Read More >

  • Available Positions

    We have one vacant position:  Scientist-Department of Molecular Pharmacology ...

    Read More >

Product Pipeline

Pipeline with 1 compound in phase III, 2 compounds in phase II, 3 compounds in phase I and 2 compounds in pre-clinical development
Since the founding in 1998, one of Zealand Pharma’s product candidates has advanced into Phase III clinical trials: ZP10 (AVE0010) for type 2 diabetes (licensed to Sanofi-Aventis Deutschland GmbH). Two compounds, ZP120 for isolated systolic hypertension and ZP1480/AP214 for post-surgical organ failure (licensed to Action Pharma A/S), have reached Phase II clinical trials. Three product candidates, ZP10-LA (AVE0010-Long Acting) for type 2 diabetes (licensed to Sanofi-Aventis Deutschland GmbH), ZP1846 for chemotherapy-induced diarrhea and ZP1609 (GAP-134) for atrial fibrillation (licensed to Wyeth Pharmaceuticals), have advanced into Phase I clinical trials. Two product candidates, ZP1848 for inflammatory bowel disease and ZP2307 for osteoporosis, are in pre-clinical development. The development of Rotigaptide (ZP123, GAP-486) for arrhythmia (licensed to Wyeth Pharmaceuticals) have been terminated after completion of Phase II clinical trials. Pipeline Graph

The following table summarizes the status of Zealand Pharma's current product pipeline.

Product Candidate

Indication

Commercial Partner

Status

AVE0010/ZP10

Type 2 diabetes

Sanofi-Aventis

Phase III - initialized 2008.

ZP120

Isolated systolic hypertension

 

Phase II - efficacy trial for acute heart failure completed in 2007.

AP214/ZP1480

Post-surgical Organ Failure

Action Pharma

Phase II – Initiated in 2008

AVE0010/ZP10-Long Acting

 

Type 2 diabetes

Sanofi-Aventis

Phase I – ongoing

ZP1846

Chemotherapy-induced diarrhea

 

Phase I – single dose, safety and tolerability trial started September 2007.

GAP-134/ ZP1609 

Atrial Fibrillation     

Wyeth 

Phase I – single dose, safety and tolerability trial started October 2007. 

ZP1848

Inflammatory Bowel Disease

 

 Preclinical

ZP2307

Osteoporosis

 

Preclinical 

To top of page

Tip a friend

Fill in the form below to tip a friend about this page.






Subscribe

When this page is updated you will be updated by e-mail.